Prospera is powered by highly optimized, proprietary cell-free DNA (cfDNA) technology. As part of your tool kit, Prospera assesses all types of kidney transplant rejection with great precision.
Read Flipbook
Watch Video
Rodolfo R. Batarsé, MD, FASN Community Nephrologist
Watch Video
Read Flipbook
Prospera assesses all types of kidney transplant rejection with great precision.
Read Flipbook
The Prospera non-invasive blood test can comprehensively identify all types of active rejection with great precision.
Read Flipbook
Prospera uses revolutionary tech to enhance the patient and physician’s ability to assess otherwise undetected rejection events that might lead to kidney loss.
Read Flipbook
Natera welcomes all insurance plans. We’re here with you at every step.
Read Flipbook
The post Advances in Donor-Derived cfDNA Testing – Promising New Data in Simultaneous Pancreas-Kidney Transplants appeared first on Natera.
Read Article
Listen
Watch Video
With Natera’s precise DNA analysis, you can effectively manage and provide the best available care to all your kidney patients.
Read Flipbook
Watch Video
Join us in understanding how the quantification of background cell-free DNA (cfDNA) may facilitate more precise rejection assessment and patients at high risk for false-negative interpretations.
Read Flipbook
Read Flipbook
Explore new technologies to transform the management of cancer patients in organ transplantation.
Read Flipbook
Watch Video
The Prospera non-invasive blood test can comprehensively identify all types of active rejection with great precision.
Read Flipbook
A step by step breakdown of how to properly collect a patient's blood for the Prospera test.
Read Flipbook
Prospera™ is a donor-derived cell-free DNA (dd-cfDNA) test for assessment of rejection in post-renal-transplant patients.
Read Flipbook
Loading More...
